[摘 要] 目的：探究染色体结构维持蛋白4（SMC4）在乳腺癌中的表达及其评估患者预后的价值。方法： 利用TIMER、GEPIA等数据库数据分析SMC4在乳腺癌组织中的表达及其与患者临床病理特征间的相关性；用免疫组化法检测SMC4蛋白在乳腺癌组织中的表达，并探讨其与乳腺癌临床病理特征之间的关系；通过Cox回归模型、Kaplan-Meier生存曲线、GEPIA数据库数据评估SMC4表达与乳腺癌患者生存期之间的关系。结果：生物信息学分析结果显示，SMC4 mRNA在乳腺癌组织中的表达水平明显高于癌旁组织（P < 0.01），并与临床分期、淋巴结转移及化疗耐药密切相关（均P < 0.05）。免疫组化法检测结果显示，在乳腺癌组织中SMC4的阳性及强阳性表达率均显著高于癌旁组织（均P < 0.05）；SMC4蛋白的高表达与乳腺癌患者年龄、临床分期和淋巴结转移密切相关（均P < 0.05）。SMC4蛋白低表达组的患者累积生存率显著高于SMC4蛋白高表达组，尤其是在HER2阳性乳腺癌患者中（均P < 0.05），且SMC4是乳腺癌患者预后的独立危险因素。结论：SMC4在乳腺癌组织中呈高表达，SMC4高表达与乳腺癌患者的淋巴结转移、临床分期及预后密切相关，可作为乳腺癌诊断与预后评判的潜在标志物。

A large number of studies in recent years have shown that long non-coding RNAs (lncRNAs) play an important regulatory role in the progression of liver fibrosis. This article briefly describes the definition, classification, and biological functions of lncRNAs and summarizes recent reports on the regulatory role of lncRNAs in liver fibrosis by acting as competitive endogenous RNA, including downregulated maternally expressed gene 3, growth arrest-specific transcript 5, and long intergenic non-coding RNA-p21 and upregulated lung adenocarcinoma-associated transcript 1, lncRNA-activated by transforming growth factor beta, plasmacytoma variant translocation 1, homeobox transcript antisense RNA, lncRNA-H19, and small nuclear RNA host gene 7, so as to provide insights into the diagnosis of liver fibrosis, the screening of therapeutic targets, and the development of clinical treatment regimens for the reversal of liver fibrosis.